Company news

Hoth Therapeutics, Inc. (NASDAQ:HOTH) news

Hoth Therapeutics, Inc. news releases on 6ix. Latest, Mar 18, 2025: Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer…

Hoth Therapeutics, Inc. (NASDAQ:HOTH) news

Press releases — page 2

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease

Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial

Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease

Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge

Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge

Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis